Direct comparison of the novel automated screening tool (AST) versus the manual screening tool (MST) in patients with already implanted subcutaneous ICD

2018 ◽  
Vol 265 ◽  
pp. 90-96 ◽  
Author(s):  
Nils Bögeholz ◽  
Paul Pauls ◽  
Fatih Güner ◽  
Niklas Bode ◽  
Alicia Fischer ◽  
...  
Keyword(s):  
Screening Tool ◽  
The Novel ◽  
Subcutaneous Icd ◽  
Automated Screening

scholarly journals Determination of Morphine in Human Urine by the Novel Competitive Fluorescence Immunoassay

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Jie Cao ◽  
Xiao-Ying Chen ◽  
Wu-Rong Zhao
Keyword(s):  
Monoclonal Antibodies ◽  
Human Urine ◽  
Screening Tool ◽  
Fluorescein Isothiocyanate ◽  
Cross Reactivity ◽  
The Novel ◽  
Fluorescence Immunoassay ◽  
Coated Plate ◽  
Efficient Screening

A competitive fluorescence immunoassay for the identification and quantification of morphine has been developed on the basis of hapten-coated plate format. Hapten was prepared through covalent conjugating a morphine derivative with albumin bovine. In the immunoassay, the hapten was inoculated on a 96-well plate and then bound with monoclonal antibodies labeled with a signal indicating dye, fluorescein isothiocyanate (FITC). Unbound FITC-antibodies were rinsed off from the plate. The fluorescein intensity decreases in the presence of morphine molecules due to the competitively binding to antibodies against hapten. The intensity is inversely correlated with the concentration of morphine. In quantitative analysis for urine samples, we obtained a linearity range of 0.2 μg/mL∼2.5 μg/mL, along with a detection limit of c.a. 1 ng/mL. The fluorescence immunoassay shows low cross-reactivity (below 10%) to 6-acetylmorphine, 3-acetylmorphine, and heroine. The developed method produced comparable results to the standard GC-MS/MS method. In conclusion, a rapid and efficient screening tool for morphine in clinical human urine has been established.

Automated screening tool for Subcutaneous Implantable Defibrillator in Brugada syndrome has a high eligibility rate which is predicted by simple electrocardiographic parameters

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
S Marelli ◽  
D Kukavica ◽  
A Mazzanti ◽  
T Chargeishvili ◽  
A Trancuccio ◽  
...  
Keyword(s):  
Positive Predictive Value ◽  
Brugada Syndrome ◽  
Predictive Value ◽  
Screening Tool ◽  
Screening Tools ◽  
Molecular Medicine ◽  
Funding Source ◽  
S Wave ◽  
High Positive Predictive Value ◽  
Automated Screening

Abstract Background Manual electrocardiographic (ECG) screening tools for the use of subcutaneous cardiac defibrillator (S-ICD) have been associated with high ineligibility rates in Brugada syndrome patients (BrS). Although recent works identified ECG parameters for S-ICD eligibility in general population, automated screening tool (AST) for S-ICD eligibility have not even been assessed in large series of patients with BrS. Purpose This study evaluates the AST-derived eligibility rates for an S-ICD in patients with BrS, and ECG parameters associated with S-ICD eligibility. Methods Screening for S-ICD eligibility was performed using AST in 194 consecutive patients with BrS. Eligibility was defined when at least one of the three vectors was acceptable both in supine and standing position. Twelve-lead ECGs were registered during the screening. ECG parameters associated with AST eligibility were identified using multivariable logistical regression. Results Our study population consisted of 194 patients, with male preponderance (n=165/194; 85%); and were 43±12 years old at the time of screening. Majority of patients presented a spontaneous type 1 pattern during screening (n=128/194; 66%), with an average pattern height of 3±3 mm. Remarkably, 93% of patients passed the screening with AST. No differences in eligibility rates in terms of gender (93% males vs. 93% females eligible; p=1) and age (48±9 years non-eligible vs. 42±12 eligible; p=0.07) existed. Notably, our eligibility rate was 2.5 times higher than rates reported in literature when using manual screening tools (p=0.023). Independent 12-lead ECG parameters (Table) associated with AST eligibility were duration of S wave <80 ms in aVF and R/T ratio ≥3 in lead II (Figure), which have a high positive predictive value (97% and 99%, respectively) for screening eligibility. Conclusions Most BrS patients (93%) are eligible for S-ICD when AST is used. S wave <80 ms in aVF, and R/T ratio ≥3 in lead II have a high positive predictive value for S-ICD eligibility. Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): The Italian Ministry of Research and University Dipartimenti di Eccellenza 2018–2022 grant to the Molecular Medicine Department (University of Pavia)

The novel geriatric screening tool and retrospective validation in older patients with cancer

2014 ◽  
Vol 5 ◽  
pp. S16-S17
Author(s):  
J.W. Kim ◽  
S.-H. Kim ◽  
Y.J. Kim ◽  
K.-W. Lee ◽  
J.-O. Lee ◽  
...  
Keyword(s):  
Older Patients ◽  
Screening Tool ◽  
The Novel ◽  
Patients With Cancer ◽  
Geriatric Screening

scholarly journals Identification of human gene research articles with wrongly identified nucleotide sequences

2022 ◽  
Vol 5 (4) ◽  
pp. e202101203
Author(s):  
Yasunori Park ◽  
Rachael A West ◽  
Pranujan Pathmendra ◽  
Bertrand Favier ◽  
Thomas Stoeger ◽  
...  
Keyword(s):  
Nucleotide Sequence ◽  
Screening Tool ◽  
Human Gene ◽  
Molecular Techniques ◽  
Research Articles ◽  
Protein Coding ◽  
Human Research ◽  
Protein Coding Genes ◽  
Non Coding Rnas ◽  
Automated Screening

Nucleotide sequence reagents underpin molecular techniques that have been applied across hundreds of thousands of publications. We have previously reported wrongly identified nucleotide sequence reagents in human research publications and described a semi-automated screening tool Seek & Blastn to fact-check their claimed status. We applied Seek & Blastn to screen >11,700 publications across five literature corpora, including all original publications in Gene from 2007 to 2018 and all original open-access publications in Oncology Reports from 2014 to 2018. After manually checking Seek & Blastn outputs for >3,400 human research articles, we identified 712 articles across 78 journals that described at least one wrongly identified nucleotide sequence. Verifying the claimed identities of >13,700 sequences highlighted 1,535 wrongly identified sequences, most of which were claimed targeting reagents for the analysis of 365 human protein-coding genes and 120 non-coding RNAs. The 712 problematic articles have received >17,000 citations, including citations by human clinical trials. Given our estimate that approximately one-quarter of problematic articles may misinform the future development of human therapies, urgent measures are required to address unreliable gene research articles.

scholarly journals Assessing the accuracy of machine-assisted abstract screening with DistillerAI: a user study

2019 ◽  
Vol 8 (1) ◽  
Author(s):  
Gerald Gartlehner ◽  
Gernot Wagner ◽  
Linda Lux ◽  
Lisa Affengruber ◽  
Andreea Dobrescu ◽  
...  
Keyword(s):  
Language Processing ◽  
Systematic Reviews ◽  
User Study ◽  
Screening Tool ◽  
Area Under The Curve ◽  
Reference Standard ◽  
Processing Technologies ◽  
Screening Approach ◽  
Automated Screening ◽  
Abstract Screening

Abstract Background Web applications that employ natural language processing technologies to support systematic reviewers during abstract screening have become more common. The goal of our project was to conduct a case study to explore a screening approach that temporarily replaces a human screener with a semi-automated screening tool. Methods We evaluated the accuracy of the approach using DistillerAI as a semi-automated screening tool. A published comparative effectiveness review served as the reference standard. Five teams of professional systematic reviewers screened the same 2472 abstracts in parallel. Each team trained DistillerAI with 300 randomly selected abstracts that the team screened dually. For all remaining abstracts, DistillerAI replaced one human screener and provided predictions about the relevance of records. A single reviewer also screened all remaining abstracts. A second human screener resolved conflicts between the single reviewer and DistillerAI. We compared the decisions of the machine-assisted approach, single-reviewer screening, and screening with DistillerAI alone against the reference standard. Results The combined sensitivity of the machine-assisted screening approach across the five screening teams was 78% (95% confidence interval [CI], 66 to 90%), and the combined specificity was 95% (95% CI, 92 to 97%). By comparison, the sensitivity of single-reviewer screening was similar (78%; 95% CI, 66 to 89%); however, the sensitivity of DistillerAI alone was substantially worse (14%; 95% CI, 0 to 31%) than that of the machine-assisted screening approach. Specificities for single-reviewer screening and DistillerAI were 94% (95% CI, 91 to 97%) and 98% (95% CI, 97 to 100%), respectively. Machine-assisted screening and single-reviewer screening had similar areas under the curve (0.87 and 0.86, respectively); by contrast, the area under the curve for DistillerAI alone was just slightly better than chance (0.56). The interrater agreement between human screeners and DistillerAI with a prevalence-adjusted kappa was 0.85 (95% CI, 0.84 to 0.86%). Conclusions The accuracy of DistillerAI is not yet adequate to replace a human screener temporarily during abstract screening for systematic reviews. Rapid reviews, which do not require detecting the totality of the relevant evidence, may find semi-automation tools to have greater utility than traditional systematic reviews.

scholarly journals Coronaviruses and the Chemical Senses: Past, Present, and Future

2020 ◽  
Vol 45 (6) ◽  
pp. 415-422 ◽  
Author(s):  
Robert Pellegrino ◽  
Keiland W Cooper ◽  
Antonella Di Pizio ◽  
Paule V Joseph ◽  
Surabhi Bhutani ◽  
...  
Keyword(s):  
Screening Tool ◽  
Respiratory Infections ◽  
Current Evidence ◽  
The Novel ◽  
Chemical Senses ◽  
True Nature ◽  
Social Trends ◽  
Chemosensory Ability ◽  
The Relationship

Abstract A wealth of rapidly evolving reports suggests that olfaction and taste disturbances may be manifestations of the novel COVID-19 pandemic. While otolaryngological societies worldwide have started to consider chemosensory evaluation as a screening tool for COVID-19 infection, the true nature of the relationship between the changes in chemosensory ability and COVID-19 is unclear. Our goal with this review is to provide a brief overview of published and archived literature, as well as the anecdotal reports and social trends related to this topic up to April 29, 2020. We also aim to draw parallels between the clinical/chemosensory symptomology reported in association to past coronavirus pandemics (such as SARS and MERS) and the novel COVID-19. This review also highlights current evidence on persistent chemosensory disturbances after the infection has resolved. Overall, our analysis pinpoints the need for further studies: (1) to better quantify olfaction and taste disturbances associated with SARS-CoV-2 infection, compared to those of other viral and respiratory infections, (2) to understand the relation between smell, taste, and chemesthesis disturbances in COVID-19, and (3) to understand how persistent are these disturbances after the infection has resolved.

scholarly journals P963S-ICD eligibility according to a novel automated screening tool and agreement with the standard manual ECG morphology tool: a preliminary multicenter experience

EP Europace ◽  
2017 ◽  
Vol 19 (suppl_3) ◽  
pp. iii198-iii198
Author(s):  
P. Francia ◽  
M. Biffi ◽  
P. De Filippo ◽  
MG. Bongiorni ◽  
A. D'onofrio ◽  
...  
Keyword(s):  
Screening Tool ◽  
Automated Screening ◽  
Ecg Morphology
Sign in / Sign up

Export Citation Format

Share Document